Operating with a strong sense of business integrity and corporate responsibility is critical to maintain trust and credibility. Bioclinica's management team is comprised of clinical trial experts with years of clinical trial, bioimaging, data management, business management, technology and pharmaceutical industry experience. Together, our clinical trial experts are dedicated to deliver better results for all of our clients' clinical trials, globally.
- John Hubbard, Ph.D., FCP, President, Chief Executive Officer and Member of the Board of Directors
- David S. Herron, Executive V.P., President, Medical Imaging & Cardiac Safety
- Maria Kraus, Executive Vice President, Corporate Development and Strategy
- David Peters, Executive Vice President and CFO
- Mukhtar Ahmed, President, eHealth Solutions
- Carmella Griffin, Executive Vice President, Global Human Resources
- Elizabeth Thiele, President, Global Clinical Research
Global Clinical Research
- Nayan Nanavati, COO, Post-Approval Research
- Dr. Hans Christian Hoeck, Chief Science Officer, Research Network
- Liz Moench, Senior Vice President, Patient Recruitment-Retention
- Sankesh Abbhi, Managing Director and Senior Vice President, Safety and Regulatory Solutions
- Colleen LoConte, Senior Vice President, Customer Relationship Management
- Andrew Masters, Senior Vice President & Chief Technology Officer
- Angelo Stortini, Senior Vice President, Business Operations
- Jay Trepanier, Senior Vice President and General Manager, Clinverse (A Bioclinica Company)
- Francois Audibert, Vice President, Global Consulting
- Steven Herne, Senior Vice President & Chief Commercial Officer
Medical Imaging and Cardiovascular Solutions Management
- J. Michael O'Neal, MD, Chief Medical Officer, Head of Oncology
- Thomas Fuerst, Chief Science Officer, Head of Musculoskeletal
- Joyce Suhy, Ph.D., Vice President and Head of Neuroscience
- Adrienne Rossi, Vice President, Business Transformation
- Chris Barron, Vice President, Engineering
- Bradley Dean, Vice President, Global Services
- Mark Endres, Head of Global Business Development
- Tanja Schubert, Ph.D., VP & General Manager Biochemical Markers, BioclinicaLab
John Hubbard, Ph.D., FCP, President, Chief Executive Officer and Member of the Board of Directors
Dr. John Hubbard is the President and CEO of Bioclinica. He is a leader in the Clinical Services and Biopharmaceutical R&D industries, with over three decades of experience including executive level positions at Pfizer, ICON, Parexel and Hoechst Marion Roussel Pharmaceuticals.
Prior to joining Bioclinica, he was Senior Vice President and Worldwide Head of Development Operations for Pfizer, where he directed and oversaw clinical trial operations and management of more than 450 clinical projects. Dr. Hubbard was also a founding member of the Board of Directors of TransCelerate Biopharma, Inc. Before joining Pfizer, Dr. Hubbard was Group President, Clinical Research Services at ICON Clinical Research, a top five global clinical research organization. He is also a Board Member of Agile Therapeutics, a Board Member of the Association of Clinical Research Organizations (ACRO), and an Advisory Board Member and Fundraising Vice-chair for the Children's Brain Tumor Foundation.
Dr. Hubbard received a Bachelor of Science degree in Biopsychology from the University of Santa Clara and a Doctorate from the University of Tennessee, with a research focus on the genetic basis of hypertension and autonomic dysfunction. He was an NIH Postdoctoral Fellow in Cardiovascular and Clinical Pharmacology at the University of Texas Health Sciences Center. Dr. Hubbard is an active member of the Society of Clinical Pharmacology and Therapeutics, a Board Certified Diplomate in Applied Pharmacology and was elected as a Fellow of the American College of Clinical Pharmacology (ACCP). He has authored/co-authored three book chapters and 76 published articles and abstracts in the areas of biopsychology, cardiovascular and autonomic pharmacology, clinical pharmacology, and global drug development.
Mr. Herron is responsible for the global strategic planning and operations of Bioclinica's medical imaging management solutions which include software and services for the electronic transfer, management, and independent review of medical images for clinical trials. Prior to joining Bioclinica, Mr. Herron served as an Executive in Residence with DW Healthcare Partners, a private equity firm focused on healthcare opportunities. Before DW Healthcare, he spent four years at CCBR-SYNARC where Mr. Herron began as VP of Sales and progressed to serve as Chief Operating Officer. Throughout his career, Mr. Herron has held positions of increasing responsibility in a variety of healthcare industries including clinical research organizations, centralized imaging laboratories, healthcare information technologies, managed care, managed pharmacy, and international consulting firms focused on information technologies, healthcare and time-loss management. Mr. Herron's healthcare experience follows a seventeen-year career in the United States military where he served in the US Marine Corps and the Adjutant General Corps USA. He was awarded three combat service medals during Operations Desert Shield and Desert Storm. Mr. Herron received his Bachelor's Degree with honors from Lipscomb University, in partnership with Vanderbilt University.
Mrs. Kraus is responsible for overseeing Bioclinica's strategic growth including mergers and acquisitions. Mrs. Kraus is also in charge of Marketing and Business Integration with her in depth knowledge of business operations. Mrs. Kraus joined Bioclinica in 1997 as Controller and has previously led accounting and finance, legal, procurement, facilities, human resources and information technology. Prior to joining the Company, Mrs. Kraus worked for PricewaterhouseCoopers. Mrs. Kraus is a member of the Board of Directors and serves as the Treasurer on the Executive Committee of the Girl Scouts of Eastern Pennsylvania. Mrs. Kraus received her bachelor's degree in Accounting from Pennsylvania State University and is a certified public accountant.
An accomplished senior finance and accounting executive with more than 25 years of financial and accounting experience and a focus in pharmaceutical services, David Peters was named Executive Vice President and CFO in 2015. Mr. Peters brings to Bioclinica deep understanding in all areas of finance, accounting and business operations within high growth and diverse business segments. He has directed all facets of accounting, financial functions and strategy in global businesses and has successfully negotiated more than 20 strategic partnership agreements. Most recently Mr. Peters was CFO at WCCT Global and prior to that was Senior Vice President of Commercial and Corporate Development and CFO of the Late Phase Clinical Group at inVentiv Health. Additionally he spent 15 years at ICON Clinical Research where he held positions including Senior Vice President of Global Finance, Vice President of Finance North and South America, and Controller. Mr. Peters is a certified public accountant with a bachelor’s degree in Accounting and Information Systems from Johnson & Wales University.
Mr. Ahmed is responsible for the eClinical Solutions Division of Bioclinica which provides software products and professional services to the clinical research industry. Mr. Ahmed joined Bioclinica in 2015, having previously served as Global Vice President at Oracle Corporation where he was responsible for leading the Life Sciences business toward transformative cloud platforms, analytics and digital medicine. Mr. Ahmed has held senior executive positions with multinational Contract Research Organizations and clinical informatics companies including Medidata, Parexel, and Kendle International. He has also held board-level, non-executive posts with National Health Service trusts in the United Kingdom and served as an industry advisor to consumer health start-ups and private equity companies. Mr. Ahmed is a Brunel University Alumni and an industry speaker on topics including scientific innovation, strategic outsourcing and business change management.
Ms. Griffin is responsible for Bioclinica's human resources functions worldwide. Ms. Griffin joined Bioclinica in April 2003 as Director, Human Resources. She has over 10 years of leadership and human resources experience in healthcare, manufacturing, distribution and service environments including management positions at Shearon Environmental Design Company and Sysco Corporation. Ms. Griffin earned her Bachelor of Arts in Mathematics from Arcadia University and her MAPP degree from the University of Pennsylvania. She is a certified Senior Professional in Human Resources through the HR Certification Institute at the Society for Human Resources Management.
Ms. Thiele is the President of Bioclinica's Global Clinical Research business segment which combines the Patient Recruitment and Retention services of Medici, the Global Site Network of CCBR, and our Post Approval Research Division. Ms. Thiele brings 16 years of leadership experience in the clinical research market, most recently coming from ICON as the President, Commercialization & Outcomes Division where she established a new business unit developing all operating procedures, as well as acquiring and integrating two top-tier global companies in the sector. Prior to this, Ms. Thiele was the Executive Vice President, Global Business Development, Clinical Research for ICON when she was the recipient of the Frost & Sullivan 2009 North American Contract Research Organizations Business Development Strategy Leadership of the Year Award.
Elizabeth (Liz) Moench, Senior Vice President,Bioclinica Patient Recruitment-Retention, founded the company MediciGlobal in 1991. Since that time, Ms. Moench has been dedicating her efforts to improving the patient recruitment and retention process in clinical trials worldwide, and leading the industry in creativity and systems for recruitment and retention on a global basis. She joined Bioclinica's leadership team in July 2015, when Bioclinica acquired Medici.
Prior to founding MediciGlobal, Ms. Moench served as Corporate Vice President of Communications and Public Affairs of the worldwide corporate management committee of Rhone‐Poulenc Rorer Pharmaceuticals managing a team based in the U.S. and in France (now Sanofi‐Aventis). She launched the first proactive patient recruitment program for the cancer drug Taxotere®. Previously, Ms. Moench was Executive Director of Public Affairs at the Swiss giant Ciba‐Geigy Pharmaceuticals Division (now Novartis).
Ms. Moench holds degrees in marketing and medical technology from Lamar University. She also holds dual citizenship in the UK and U.S.
As the president/CEO and founder, of Synowledge, Sankesh Abbhi has overseen the unprecedented and sustained growth of Synowledge since its inception in 2006. Under his lead, Synowledge has solidified its place as a global market leader in drug safety and IT services, and has established a significant presence in the North American, EMEA, and Asia Pacific regions. Prior to founding Synowledge, Sankesh held senior account management positions within Aris Global, a leading provider of integrated software solutions for life sciences companies. Sankesh is a graduate of Columbia University with a BA in Economics.
Ms. LoConte is responsible for management of the Bioclinica Customer Relationship Executive Program which leads the development and execution of a diverse range of customer loyalty and retention programs. She has extensive experience in the implementation of technology and services within the pharmaceutical sector and works with our clients to implement measures for a successful implementation. Previously Ms. LoConte provided leadership and process knowledge in multiple Vice President Positions within and through the pharmaceutical industry beginning her career with Warner-Lambert Company, now Pfizer Incorporated where she spent 18 years working on Global Compliance. Ms. LoConte possesses a Bachelor of Management from Fairleigh Dickenson University.
Mr. Masters has global responsibility for Bioclinica's eClinical software products and information technology solutions. In this role he is instrumental in evolving our product suite and transitioning to our next generation cloud and patient-centered analytics platform. Mr. Masters has more than 20 years of industry experience and previously held technology and leadership roles with DHL Express, Avnet, MCI Worldcom, and Lenovo. Mr. Masters was most recently vice president of global strategic innovation at PPD where he led new business model development for mobile, data simulation and other technologies including Preclarus™ analytics. He has an MBA from Duke University and began his technology career with the U.S. Navy in Naval research.
Mr. Stortini brings 30 years of business operations and professional services organization leadership to Bioclinica. He is instrumental to the optimization of our business operations and processes across all eClinical divisions and providing a sound operating business infrastructure. Most recently Mr. Stortini was senior vice president at roundCorner, a cloud CRM provider, and prior to this was senior practice director for Oracle's global safety practice within the life sciences and healthcare business. He has also held senior management positions with Siebel Systems, IBM, and Digital Equipment Corporation. He has a Bachelor of Science degree from LaSalle University and a Juris Doctor from Delaware Law School.
Mr. Trepanier is responsible for leading Clinverse, Bioclinica's Financial Lifecycle Solutions division. Mr. Trepanier has more than 20 years of financial and operational experience across several industry sectors including technology, healthcare, life sciences, IT, and oil and gas. Prior to joining Clinverse, Mr. Trepanier served as the Chief Financial Officer and/or Chief Operating Officer at various companies including Jones and Frank, Alphanumeric, and DataFlux. Additionally, he served as the Chief Financial Officer of Etrials Worldwide, an eclincial solutions provider to pharmaceutical companies, prior to its acquisition by Merge Healthcare. Mr. Trepanier received his MBA from Southern New Hampshire University, a BS in Accounting from West Virginia University, and a BS in Business from the University of New Hampshire. In addition, he is a licensed CPA and holds certifications in Six Sigma and project management. Mr. Trepanier has also served on several boards of directors including the UNC Children's Hospital, DataFlux, and Alphanumeric.
Mr. Audibert leads Bioclinica's global eHealth Solutions consulting practice specializing in data sciences, safety system and process, and overall life sciences strategy. Mr. Audibert, a 30-year industry veteran, is among the top thought leaders in life sciences technology. He brings a unique blend of technology, strategy and business expertise to Bioclinica, and has worked on some of the world's largest drug safety implementations within a global regulatory and distribution environment. Prior to joining Bioclinica, Mr. Audibert was most recently Vice President of Pharmacovigilance at HighPoint Solutions, and prior to this was Safety Solutions Director at Oracle where led the safety and surveillance teams into new offerings. Mr. Audibert is a graduate of Conservatoire National des Arts et Métiers.
Mr. Herne leads global business development for Bioclinica's eHealth Solutions business segment development. Prior to joining Bioclinica, Mr. Herne was most recently Chief Commercial officer at ERT where he was an executive member of the global leadership team, responsible for creating and executing the long-term strategic growth plan across all business lines. Previously Mr. Herne held the position of Senior Vice President, Global Business Development at Icon where he was a member of the executive team tasked with directing the development and prioritization of business generated through key new strategic ventures. Mr. Herne was also with Covance as Vice President, Europe and Asia Pacific Business Development where he played a key role in the development and implementation of the company's European Clinical Development business. Mr. Herne has a master's degree in Pharmaceutical Analysis from the University of Strathclyde and a bachelor's degree in Pharmacy Instrumentation from Glasgow Caledonian University.
Dr. O'Neal provides leadership and oversight to Bioclinica's staff radiologists and external radiology consultants. He holds responsibility for managing the organizational planning and operational needs of the Medical Affairs department, overseeing service quality, physician training, and process improvement. Dr. O'Neal joined CoreLab Partners in 2004 as a diagnostic radiologist with more than 20 years of practice experience and has continued to provide key leadership through the 2013 Bioclinica/CoreLab Partners merger. Before joining the company, Dr. O'Neal served as Chairman for the Department of Radiology at the Hospital Center at Orange from 1996-2004. Dr. O'Neal is certified by the American Board of Radiology and has been published in the Journal of Bone and Joint Surgery. He is a member of several professional organizations, including the RSNA and the American College of Radiology. Dr. O'Neal is a graduate of Rutgers University and the Universidad Autonoma de Guadalajara in Mexico, where he earned his M.D (1981).
Dr. Thomas Fuerst leads the design and scientific oversight of musculoskeletal clinical trials for Bioclinica. Dr. Fuerst received his Ph.D. in medical physics from the University of Wisconsin at Madison and has more than 13 years of research experience in bone densitometry, vertebral fracture methods and body composition assessment with a focus on multicenter clinical trials. Prior to joining Bioclinica, he was a faculty member of the University of California, San Francisco, where he served as Director of the Quality Assurance Center and as Associate Director of the Osteoporosis and Arthritis Research Group (OARG). While at UCSF, he successfully coordinated the collection, quality control and centralized analysis of densitometry scans and imaging data for international, multi-center Phase II and Phase III clinical trials. Dr. Fuerst is also the co-founder of the imaging core lab Synarc, where he served as Scientific Director.
As an active member of the International Committee for Standards in Bone Measurement, Dr. Fuerst has worked to improve, standardize, and advance bone density technologies. He routinely consults with industry and government agencies on the use of DXA to evaluate bone mineral density and body composition.
Dr. Joyce Suhy leads the design and technical oversight of neuroscience clinical trials and provides training to staff involved in these studies. She has been working in the field of MRI and Spectroscopy for over 20 years and has a wealth of experience managing neuroscience clinical trials. Prior to joining Bioclinica, Dr. Suhy worked at Synarc, where she was the VP of Neuroscience, and at SurroMed, Inc. where she was a Clinical Research Specialist responsible for the development, design, and evaluation of a standardized protocol for a multiple sclerosis program.
Dr. Suhy received a PhD in Biochemistry from Loyola University and completed a post-doctoral Research Fellowship in the Department of Radiology at the University of California at San Francisco where her work focused on utilizing MR spectroscopy and imaging to quantify metabolites within the human brain as a method to diagnose and predict the onset of neurodegenerative diseases such as epilepsy, multiple sclerosis, and amyotrophic lateral sclerosis.
Dr. Suhy is a recipient of many honors and grant awards including the Co-principal investigator NIH RO1 Grant, the Principal Investigator NIH National Research Service Award and the Principal Investigator National MS Society Fellowship. She has authored numerous journal articles and book chapters in the neuroscience therapeutic area and has participated on several expert panels to advance the use of imaging in clinical trials.
Mrs. Rossi is responsible for providing leadership and oversight to the business innovation and transformation team to align and implement operational efficiency and productivity projects with the organizations strategic objectives and initiatives. She has extensive experience in clinical trial operations and project management and has functioned as Project Director for numerous clinical trials across various therapeutic areas at Bioclinica.
Prior to joining Bioclinica, Mrs. Rossi has held positions of increasing responsibility at Core Lab Partners including Senior Project Manager of Clinical Operations and Director of Clinical Project Management. She has also served as Clinical Study Manager for Ophthalmic clinical studies at Bausch & Lomb. Ms. Rossi possesses a Bachelor of Science in Public Health and in Women's Studies from Rutgers University.
Mr. Barron is responsible for Bioclinica's Imaging and Biomarkers technology solutions. In this role, he leads and has oversight to system development, validation, product management, infrastructure and support. Mr. Barron has over 10 years of experience in medical imaging for clinical trials and more than 20 years of experience in technology and software engineering. Mr. Barron was previously Sr. Director of Engineering for Synarc. Prior to this, he worked as a Lead Consultant for Proxicom/Dimension Data implementing enterprise applications for a number of large Healthcare and Financial Services companies. Mr. Barron received his Bachelor’s degree in Chemistry from Oberlin College.
Mr. Endres is responsible for global business development for the Medical Imaging Solutions Division of Bioclinica. Mr. Endres began his career at Bioclinica (formerly Bio-Imaging Technologies, Inc.) in May 1992 as a Clinical Research Associate. Mr. Endres has held many positions including Senior Imaging Consultant, Manager of Clinical Imaging Services, Associate Director of Core Lab Services, Director of Alliance Management and Director of Business Development. Prior to joining the Company, he spent 3 years as a Staff Nuclear Medicine Technologist for the Medical Center Hospital of Vermont. Mr. Endres earned his Bachelor's degree in Nuclear Medicine Technology from the University of Wisconsin and is a certified NMTCB.
Dr. Schubert leads the Molecular Marker division of Bioclinica and is responsible for all operational and organizational activities, overseeing service quality, study management, process improvements and regulatory compliance. She is actively engaged in business development and client discussions advising in implementing biochemical markers in clinical trials. Dr. Schubert oversees the laboratory activities and serves as accredited Laboratory Director for the College of American Pathologists. Prior to her current position, Dr. Schubert joined legacy Synarc Laboratory in 2006 as Head of the Project Management Department and was responsible for all operational aspects of a clinical trial management.
Dr. Schubert is a trained Pharmacist and received a PhD in Natural Sciences from the Ludwig-Maximilians-Universität in Munich, Germany.